Kyowa Kirin's Q1 profits plunge amidst strategic investments
Kyowa Kirin (TSE:4151) reported a significant decrease in first-quarter profits for the fiscal year ending December 2025, with profits attributable to owners of the parent declining 57.9% to ¥6.167 billion. Core operating profit also saw a substantial decrease of 50.5%, falling to ¥8.6 billion. While revenue experienced a marginal dip of 0.8% to ¥104.7 billion, the company is actively investing in its pipeline. Research and development expenses jumped by 22% to ¥28.6 billion, reflecting Kyowa Kirin's commitment to advancing its key projects. The company's pipeline features rocatilinimab, a monoclonal antibody for atopic dermatitis and prurigo nodularis in Phase III trials and ziftomenib, a menin inhibitor for AML currently under regulatory review in the US. The company reaffirmed its full-year forecast, projecting revenue of ¥478.0 billion and profit attributable to owners of the parent of ¥57.0 billion, with a continued focus on global strategic products and strategic collaborations to drive future growth. The interim dividend forecast remains unchanged at ¥30 per share.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
News Alerts
Get instant email alerts when Kyowa Kirin publishes news
Free account required • Unsubscribe anytime